Literature DB >> 23750028

Immunology and bone.

Lynett Danks1, Hiroshi Takayanagi.   

Abstract

It is now well acknowledged that the immune and skeletal systems interact and affect one another during developmental physiology and pathology. With the aid of modern conditional gene targeting and transgenic technologies, this field of interdisciplinary research, known as osteoimmunology, is rapidly advancing. Numerous bone phenotypes have been described in immune-compromised gene-deficient mice and, albeit to a lesser extent, immune deficiencies exist in osteo-compromised gene-deficient mice, suggesting that bone cells themselves actually regulate the development of immune cells directly. In this review, I discuss the essential role of key cytokines, signalling transduction pathways and transcription factors during immune and bone development, and how pathology driven dysregulation of these shared mechanisms can lead to clinical manifestations. Diseases that are within the remit of osteoimmunology continue to cause significant morbidity, for example, rheumatoid arthritis, osteoporosis, multiple myeloma and breast/prostate cancer. The complexity and overlapping cellular and molecular interactions between the immune and bone tissues, mean that despite fervent research of these diseases, it remains a major challenge to discover therapeutics that can specifically target one system without detrimentally affecting the other.

Entities:  

Keywords:  RANKL; T cell; haematopoietic stem cell; osteoblast; osteoclast

Mesh:

Substances:

Year:  2013        PMID: 23750028     DOI: 10.1093/jb/mvt049

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  38 in total

1.  A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.

Authors:  Sapna P Patel; Dae Won Kim; Roland L Bassett; Suzanne Cain; Edwina Washington; Wen-Jen Hwu; Kevin B Kim; Nicholas E Papadopoulos; Jade Homsi; Patrick Hwu; Agop Y Bedikian
Journal:  Cancer Immunol Immunother       Date:  2017-06-13       Impact factor: 6.968

2.  BSNXD modulates mesenchymal stem cell differentiation into osteoblasts in a postmenopausal osteoporotic mouse model.

Authors:  Xue-Min Qiu; Ling Wang; Yu-Yan Gui; Ying-Ping Xu; Da-Jin Li
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 3.  Modulation of osteoclast differentiation and bone resorption by Rho GTPases.

Authors:  Heiani Touaitahuata; Anne Blangy; Virginie Vives
Journal:  Small GTPases       Date:  2014-03-10

4.  A DNA segment spanning the mouse Tnfsf11 transcription unit and its upstream regulatory domain rescues the pleiotropic biologic phenotype of the RANKL null mouse.

Authors:  Melda Onal; Kathleen A Bishop; Hillary C St John; Allison L Danielson; Erin M Riley; Marilina Piemontese; Jinhu Xiong; Joseph J Goellner; Charles A O'Brien; J Wesley Pike
Journal:  J Bone Miner Res       Date:  2015-05       Impact factor: 6.741

5.  The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.

Authors:  Kenta Watanabe; Michiko Hirata; Tsukasa Tominari; Chiho Matsumoto; Hidenori Fujita; Kazuhiko Yonekura; Gillian Murphy; Hideaki Nagase; Chisato Miyaura; Masaki Inada
Journal:  J Biol Chem       Date:  2016-08-18       Impact factor: 5.157

6.  Staphylococcus aureus and Acinetobacter baumannii Inhibit Osseointegration of Orthopedic Implants.

Authors:  Hyonmin Choe; Joscelyn M Tatro; Bryan S Hausman; Kristine M Hujer; Steve H Marshall; Ozan Akkus; Phillip N Rather; Zhenghong Lee; Robert A Bonomo; Edward M Greenfield
Journal:  Infect Immun       Date:  2022-01-31       Impact factor: 3.609

7.  Proinflammatory M1 Macrophages Inhibit RANKL-Induced Osteoclastogenesis.

Authors:  Tsuguno Yamaguchi; Alexandru Movila; Shinsuke Kataoka; Wichaya Wisitrasameewong; Montserrat Ruiz Torruella; Michiaki Murakoshi; Shinya Murakami; Toshihisa Kawai
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

8.  Association of Acroosteolysis With Enhanced Osteoclastogenesis and Higher Blood Levels of Vascular Endothelial Growth Factor in Systemic Sclerosis.

Authors:  Jin Kyun Park; Andrea Fava; John Carrino; Filippo Del Grande; Antony Rosen; Francesco Boin
Journal:  Arthritis Rheumatol       Date:  2016-01       Impact factor: 10.995

9.  Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis.

Authors:  Jerzy Świerkot; Katarzyna Gruszecka; Agnieszka Matuszewska; Piotr Wiland
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2015-04-03       Impact factor: 4.291

10.  Oridonin ameliorates inflammation-induced bone loss in mice via suppressing DC-STAMP expression.

Authors:  Bin-Hua Zou; Yan-Hui Tan; Wen-de Deng; Jie-Huang Zheng; Qin Yang; Min-Hong Ke; Zong-Bao Ding; Xiao-Juan Li
Journal:  Acta Pharmacol Sin       Date:  2020-08-04       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.